Finally, cancer patients have real-time access to their medical records
Recent changes to patients’ data rights enable xCures’ platform to automatically retrieve patient medical records from institutions and generate powerful care summaries. EINPressWire, 11/8/22 Last month, the 21st Century Cures Act forced healthcare organizations to provide patients quick and easy access to their health records in a digital format. In response to the news, xCures […]
xCures and mProbe partner to help cancer patients determine optimal treatments
xCures partners with mProbe, to leverage their targeted proteomics platform for profiling individual patients’ cancer tissues for actionable drug targets xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and […]
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007
Oblato’s first-in-class small molecular OKN-007 will be available through a newly opened compassionate use protocol. xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of […]
Pancreatic Cancer Patients Will Now Have Remote Access to Precision Nutrition Trial Through New Partnership
xCures and Vault Health integration creates a decentralized platform to benefit pancreatic cancer research and facilitate enrollment in Faeth’s NEAAR-001 study xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. NEAAR-001 is a clinical trial […]
xCures partners with Travera to support advanced carcinoma patients and their physicians
Decentralized clinical trial for patients with advanced carcinomas helps determine their cancer’s response to specific drugs [EIN Presswire, July 19, 2022] xCures, Inc. is proud to announce their partnership with Travera, and the launch of a decentralized clinical trial that provides patients with advanced carcinoma a functional profile of their cancer cells. Advanced carcinoma patients […]
xCures and Novocure® partner to better understand quality of life in glioblastoma
Innovative collaboration focused on developing the first comprehensive Quality of Life dataset for glioblastoma patients [EIN PressWire June 21, 2022] xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance between both oncology companies will […]
Prognos Health and xCures Partner to enable Access to Real World Oncology Datasets
The new collaboration focuses on improving outcomes by continuous learning from every patient’s journey across diverse datasets CHICAGO, IL, UNITED STATES, June 3, 2022 /EINPresswire/ Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access and insights for life science […]
xCures joins C-Path’s Cure Drug Repurposing Collaboratory to Deliver AI-enabled Data Abstraction of Health Records
Members of CDRC will be able to utilize xCures’ technology to quickly abstract and structure clinical data to support drug repurposing studies in rare cancer. xCures today announced has joined the Critical Path Institute’s (C-Path) Cure Drug Repurposing Collaboratory (CDRC). CRDC is operated by C-Path as a public-private partnership with the U.S. Food and Drug […]
Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
xCures to use tumor sequencing information and its platform to pair patients with available treatment options Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that […]
xCures announces real world biomarker study for patients with FGFR-mutant bladder cancer receiving Balversa®
Tyra Biosciences supported study investigates if non-invasive blood and urine samples provide biomarkers to assess clinical response to erdafitinib treatment Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The study is supported by Tyra […]
xCures and BioSpark partner to boost Real World Oncology Data offerings
New partnership allows for a 40,000+ patient dataset to unlock new insights into cancer treatments and outcomes. xCures, Inc. and BioSpark, Inc. are proud to announce their strategic partnership to harmonize and commercialize a joint oncology Real World Data (RWD) offering. The partnership unlocks new insights into the treatment and outcomes of cancer patients through […]
TARGET: Cancer Podcast to be hosted by media personality Dr. Sanjay Juneja – TheOncDoc
Oncologist and cancer educator Dr. Sanjay Juneja will host xCures’ informative podcast on cancer and technology February 17, 2022 – Oakland, CA. – xCures, a direct-to-patient, and direct-to-physician oncology platform, is proud to announce Sanjay Juneja, MD, as the host to their TARGET: Cancer podcast. Dr. Sanjay Juneja is a leading oncologist and cancer educator with a […]
xCures Webinar: Implications of new FDA draft guidance on real-world data explained
TORONTO (PRWEB) DECEMBER 01, 2021 The FDA has issued two new draft guidance documents on the use and structure of real-world data in regulatory decision-making. While real-world data has been around for many years, in this webinar the xCures speakers will recap the guidance and discuss what this means for the use of real-world data going […]
xCures presents the results of their oncology platform at the 2021 SNO Annual Meeting
xCures’ poster at the SNO meeting will show results from their XCELSIOR platform of real-world datasets and clinical outcomes in CNS cancer patients. Today, xCures announced their poster presentation at the 26th Annual Meeting of the Society for Neuro-Oncology, held from the 18th to the 21st of November. The Society for Neuro-Oncology (SNO) is a […]
xCures hosts xDECIDE webinars
xCures is inviting the oncology community to register for a 25-minute webinar introducing a new clinical decision support tool: xDECIDE. Oncology providers now have access to a toolkit that offers tailored recommendations for treatment options and personalized patient health summaries. To accompany the launch of the platform, Dr. Juneja discusses what these tools are and […]
xCures launches xDECIDE to help oncologists find better treatment options for their patients
Portal helps oncologists find the most recent and relevant therapeutic options for advanced cancer patients so they can focus on treatment evaluation xCures announced today the release of xDECIDE, the latest in the company’s suite of tools to empower oncologists and their teams to identify the most suitable, personalized treatment options for advanced cancer patients […]
Jaime Leandro Foundation treats first cancer patient with personalized neoantigen peptide vaccine under expanded access through xCures
First-of-its-kind consortium enables cancer patients to receive anticancer vaccine therapy through compassionate use. The Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF) and partners announce the treatment of the first cancer patient with a personalized neoantigen vaccine through a self-pay compassionate use program. JLF is a 501(c)3 non-profit organization whose mission is to make personalized […]
xCures raises $12.69 million in Series A funding for their AI-powered precision oncology platform
xCures has helped 1000+ advanced cancer patients and their oncologists with treatment options and recently enabled direct access to the platform through xINFORM Oakland, June 23rd, 2021 (PRNewswire) – xCures Inc., the leader in the patient-centric use of artificial intelligence (AI) and predictive modeling, announced today that it has raised $12.69 million in Series A […]